The psychedelic experience and treatment‐resistant depression
World Psychiatry September 15, 2023 DOI: 10.1002/wps.21140 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | Depression Psilocybin Serotonin |
| Keywords | Mood Hallucinogen Randomized controlled trial Receptor |
| Key points | Argues that interest in serotonergic agonists such as psilocybin for treatment-resistant depression has grown faster than the supporting evidence, and describes a proposed mechanism whereby psilocybin, once metabolized to psilocin, activates 5-HT2A receptors, enhances GABA function in local cortical circuits, and increases connectivity between functional brain modules. |
Abstract
Interest in the use of serotonergic agonists such as psilocybin in treatment-resistant depression (TRD) has grown more quickly than the evidence on which to base a final opinion, as emphasized by McIntyre et al1 in their review. Psilocybin, once metabolized to psilocin, activates 5-HT2A receptors, enhancing GABA function in local circuits in the cortex and increasing connectivity between functional modules in the brain.
Citations in the library
Cited by 3
- Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile Biological Psychiatry: Cognitive Neuroscience and Neuroimaging February 1, 2024
- Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review. Frontiers in Psychiatry 2024
- Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia. Australian & New Zealand Journal of Psychiatry October 1, 2024
Cites 7
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV) PLoS One August 31, 2010
- The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans Pharmacopsychiatry July 1, 1998
- Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review Neuroscience & Biobehavioral Reviews September 1, 2022
and 2 more in the library